Case Studies

GRG Health captured real-world insights from 30 senior dermatology KOLs across Japan, Saudi Arabia, and the UAE. The study uncovered key concerns around long-term efficacy, integration challenges, and limited awareness of T-cell depleting therapies in emerging markets. Higher pipeline awareness in Japan highlighted the value of clinical trial exposure and early academic engagement. These insights are already supporting more tailored launch strategies and informed stakeholder engagement for next-generation Atopic Dermatitis therapies.